Abstract:HIV remains a health challenge worldwide, partly because of the continued development of resistance to drugs. Therefore, it is urgent to find new HIV inhibitors and targets. Apolipoprotein B mRNA-editing catalytic polypeptide-like 3 family members (APOBEC3) are important host restriction factors that inhibit HIV-1 replication by their cytidine deaminase activity. HIV-1 viral infectivity factor (Vif) promotes proteasomal degradation of APOBEC3 proteins by recruiting the E3 ubiquitin ligase complex, in which core-binding factor β (CBFβ) is a necessary molecular chaperone. Interrupting the interaction between Vif and CBFβ can release APOBEC3 proteins to inhibit HIV-1 replication and may be useful for developing new drug targets for HIV-1. In this study, we identified a potent small molecule inhibitor CBFβ/Vif-3 (CV-3) of HIV-1 replication by employing structure-based virtual screening using the crystal structure of Vif and CBFβ (PDB: 4N9F) and validated CV-3's antiviral activity. We found that CV-3 specifically inhibited HIV-1 replication (IC<sub>50</sub> = 8.16 µm; 50% cytotoxic concentration >100 µm) in nonpermissive lymphocytes. Furthermore, CV-3 treatment rescued APOBEC3 family members (human APOBEC3G (hA3G), hA3C, and hA3F) in the presence of Vif and enabled hA3G packaging into HIV-1 virions, which resulted in Gly-to-Ala hypermutations in viral genomes. Finally, we used FRET to demonstrate that CV-3 inhibited the interaction between Vif and CBFβ by simultaneously forming hydrogen bonds with residues Gln-67, Ile-102, and Arg-131 of CBFβ. These findings demonstrate that CV-3 can effectively inhibit HIV-1 by blocking the interaction between Vif and CBFβ and that this interaction can serve as a new target for developing HIV-1 inhibitors.

Aromatic disulfides as potential inhibitors against interaction between deaminase APOBEC3G and HIV infectivity factor

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Small‐Molecule APOBEC3G DNA Cytosine Deaminase Inhibitors Based on a 4‐amino‐1,2,4‐triazole‐3‐thiol Scaffold

Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein.

Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction

Synthesis, Biological Evaluation and Molecular Docking Study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide Derivatives As Potent HIV-1 Vif Antagonists.

Could HIV-Vif complex docking ligands protect human-A3G?

Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation

Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Functional analysis of the two cytidine deaminase domains in APOBEC3G.

Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.

Zinc Chelation Inhibits HIV Vif Activity and Liberates Antiviral Function of the Cytidine Deaminase APOBEC3G.

A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction

Structural Basis of Antagonism of Human APOBEC3F by HIV-1 Vif

Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1

Conserved and Non-Conserved Features of HIV-1 and SIVagm Vif Mediated Suppression of APOBEC3 Cytidine Deaminases.

Structural basis of HIV-1 Vif-mediated E3 ligase targeting of host APOBEC3H

Synthesis and characterization of gold(I) thiolate derivatives and bimetallic complexes for HIV inhibition

Design, Synthesis and Biological Evaluation of Indolizine Derivatives As HIV-1 VIF–ElonginC Interaction Inhibitors

Crystal Structure of the C-terminal Deaminase Domain of APOBEC3G: Implications and Projections

APOBEC proteins and intrinsic resistance to HIV-1 infection